AGN 3.51% 88.5¢ argenica therapeutics limited

Ann: Positive Preclincal Data on Efficacy in New Indication, page-8

  1. 162 Posts.
    lightbulb Created with Sketch. 410
    In the recent preso, the company said the phase 1 trial would start in Q2 this year (so Mar-Jun timeline).

    But, I think someone mentioned here the trial was pushed back until this time next year?

    Can anyone elaborate?

    Cheers
 
watchlist Created with Sketch. Add AGN (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.